Mapping the Future of Glaucoma, edited by Robert N. Weinreb
IGR 10-2 September, 2008
Introduction, by R.N. Weinreb
Keynote lecture, by M. Berelowitz
Session 1: Different outcomes linked to IOP
Lessons learnt from diurnal blood pressure variability, by T. Pickering
Keypoints
Current limitations in measuring IOP in glaucoma, by T. Aung
Continuous monitoring of IOP, by A.J. Sit
Keypoints
Point-Counterpoint: Ocular perfusion pressure, a risk factor for progression?
How does blood pressure relate to eye pressure, and to glaucoma prevalence, incidence and progression? by H.A. Quigley
Is there enough evidence to establish the role of perfusion pressure in glaucoma? by F. Topouzis
Keypoints
Session 2: Innovation in drug delivery
Osteoporosis: development and utility of pharmacotherapy, by R. Lindsay
Keypoints
Innovation in drug delivery systems, by D. Paggiarino
Keypoints
Session 3: Strengthening the link between IOP efficacy and progression
Biomarkers for clinical trials: lessons from Alzheimer's disease, by M.W. Weiner
Considering how progression trials could be shortened: what is the role of newer technologies? by F.A. Medeiros
Keypoints
Considering how progression trials could be shortened: what is the role of different analytical methods? by B. Chauhan
Keypoints
Functional endpoints in the glaucoma patient, by P.P. Lee
Keypoints
Participants
